Xanthine derivatives as selective HM74A agonists

Details for Australian Patent Application No. 2006278216 (hide)

Owner SmithKline Beecham Corporation

Inventors Mason, Andrew McMurtrie; Rahman, Shahzad Sharooq; Hatley, Richard Jonathan Daniel; Smith, Ian Edward David; Liddle, John; Pinto, Ivan Leo; Heer, Jag Paul

Agent Davies Collison Cave

Pub. Number AU-A-2006278216

PCT Pub. Number WO2007/017262

Priority 0614569.2 21.07.06 GB; 0516464.5 10.08.05 GB; 0607736.6 19.04.06 GB

Filing date 8 August 2006

Wipo publication date 15 February 2007

International Classifications

C07D 473/06 (2006.01) Heterocyclic compounds containing purine ring systems

A61K 31/495 (2006.01) - having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine

A61P 3/00 (2006.01) Drugs for disorders of the metabolism

A61P 9/00 (2006.01) Drugs for disorders of the cardiovascular system

C07D 473/04 (2006.01) Heterocyclic compounds containing purine ring systems

Event Publications

28 February 2008 PCT application entered the National Phase

  PCT publication WO2007/017262 Priority application(s): WO2007/017262

19 August 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006278223-An apparatus for surface electrical stimulation and stabilization to treat disorders of the joints

2006278215-Xanthine derivatives as selective HM74A agonists